PharmaShots | Incisive News in 3 Shots

Subscribe Now

AbbVie

AbbVie’s Rinvoq (upadacitinib) Receives the CHMP’s Recommendation for Approval to Treat Active Non-Radiographic Axial Spondyloarthritis

AbbVie’s Rinvoq (upadacitinib) Receives the CHMP’s Recommendation for Approval to Treat Active Non-Radiographic Axial Spondyloarth...

June 27, 2022

AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval as the First Specific Interleukin-23 to Treat Moderately to Severely Active Crohn's Disease

AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval as the First Specific Interleukin-23 to Treat Moderately to Se...

June 20, 2022

AbbVie Presents Five-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia at EHA 2022

AbbVie Presents Five-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia at...

June 10, 2022

AbbVie Published Results of Rinvoq (upadacitinib) & Skyrizi (risankizumab) in Multiple P-III Induction and Maintenance Studies for UC & CD in The Lancet

AbbVie Published Results of Rinvoq (upadacitinib) & Skyrizi (risankizumab) in Multiple P-III Induction and Maintenance Studies for...

May 27, 2022

AbbVie Signs an Exclusive Worldwide License Option Agreement with Cugene for CUG252 to Treat Autoimmune Diseases

AbbVie Signs an Exclusive Worldwide License Option Agreement with Cugene for CUG252 to Treat Autoimmune Diseases

May 17, 2022

AbbVie Reports Results of Rinvoq (upadacitinib) P-III (U-ENDURE) Maintenance Study for the Treatment of Crohn's Disease

AbbVie Reports Results of Rinvoq (upadacitinib) P-III (U-ENDURE) Maintenance Study for the Treatment of Crohn's Disease

May 12, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us